1. Advancement in the Nose-to-Brain Drug delivery of FDA-approved drugs for the better management of Depression and Psychiatric disorders.
- Author
-
Upadhyay R, Ghosh P, and Desavathu M
- Subjects
- Humans, Animals, Depression drug therapy, United States Food and Drug Administration, Drug Approval, United States, Nasal Mucosa metabolism, Nasal Mucosa drug effects, Nanoparticles administration & dosage, Administration, Intranasal, Antidepressive Agents administration & dosage, Antidepressive Agents pharmacokinetics, Drug Delivery Systems, Brain metabolism, Brain drug effects, Antipsychotic Agents administration & dosage, Antipsychotic Agents pharmacokinetics, Antipsychotic Agents chemistry, Mental Disorders drug therapy
- Abstract
The Prevalence of Depressive and Psychiatric disorders is increasing globally, and despite the availability of numerous FDA-approved drugs, treatment remains challenging. Many conventional antidepressants and antipsychotic formulations face issues such as low solubility, high first-pass metabolism, poor bioavailability, inadequate blood-brain barrier penetration, and systemic side effects. These challenges lead to reduced efficacy, slower onset of action, and decreased patient adherence to treatment. To address these problems, recent studies have explored the nose-to-brain route for drug delivery. This method offers several advantages, including non-invasive drug administration, direct access to the brain, rapid onset of action, reduced systemic exposure and side effects, avoidance of first-pass metabolism, enhanced bioavailability, precision dosing, and improved patient compliance. The formulations used for this approach include lipidic nanoparticles, polymeric nanoparticles, nasal gels, cubosomes, niosomes, polymeric micelles, nanosuspensions, nanoemulsions, nanocapsules, and elastosomes. This review analyzes and summarizes the published work on the nose-to-brain delivery of FDA-approved antidepressants and antipsychotic drugs, with a focus on the preparation, characterization, pharmacokinetics, pharmacodynamics, and toxicity profiling of these nanoformulations., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF